Your browser doesn't support javascript.
loading
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Naranbhai, Vivek; Viard, Mathias; Dean, Michael; Groha, Stefan; Braun, David A; Labaki, Chris; Shukla, Sachet A; Yuki, Yuko; Shah, Parantu; Chin, Kevin; Wind-Rotolo, Megan; Mu, Xinmeng Jasmine; Robbins, Paul B; Gusev, Alexander; Choueiri, Toni K; Gulley, James L; Carrington, Mary.
Afiliação
  • Naranbhai V; Massachusetts General Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Centre for the AIDS Programme of Research In South Africa, Durban, South Africa.
  • Viard M; Basic Science Programme, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD, USA.
  • Dean M; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Groha S; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Braun DA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Labaki C; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Shukla SA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Yuki Y; Basic Science Programme, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD, USA.
  • Shah P; Bioinformatics, Department of Translational Medicine and Global Clinical Development, EMD Serono Research and Development Institute, Merck KGaA, Darmstadt, Germany.
  • Chin K; Immunooncology, EMD Serono Research and Development Institute, Merck KGaA, Darmstadt, Germany.
  • Wind-Rotolo M; Bristol-Myers Squibb, New York, NY, USA.
  • Mu XJ; Computational Biology, Pfizer, San Diego, CA, USA.
  • Robbins PB; Translational Oncology, Pfizer, San Diego, CA, USA.
  • Gusev A; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gulley JL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Carrington M; Basic Science Programme, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Electronic address: carringm@mail.nih.gov.
Lancet Oncol ; 23(1): 172-184, 2022 01.
Article em En | MEDLINE | ID: mdl-34895481
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno HLA-A3 / Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno HLA-A3 / Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article